Sitebridge Research Inc. is excited to announce the ongoing clinical research study titled “ACCLAIM-Lp(a): A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse ...
The proposed mechanisms for the effects of POM3 on the lipoprotein lipid ... LDL-C treatment goal Non-HDL-C treatment goal if TG ≥ 2.26 mmol/l Moderately high risk: 2+ risk factors ¶ (10- ...